Pliant Therapeutics Statistics
Total Valuation
PLRX has a market cap or net worth of $682.17 million. The enterprise value is $337.87 million.
Important Dates
The next estimated earnings date is Wednesday, February 26, 2025, after market close.
Earnings Date | Feb 26, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
PLRX has 60.85 million shares outstanding. The number of shares has increased by 7.77% in one year.
Current Share Class | 60.85M |
Shares Outstanding | 60.85M |
Shares Change (YoY) | +7.77% |
Shares Change (QoQ) | +0.58% |
Owned by Insiders (%) | 2.92% |
Owned by Institutions (%) | 83.79% |
Float | 46.80M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | 955.42 |
PB Ratio | 1.97 |
P/TBV Ratio | 1.97 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.26, with a Debt / Equity ratio of 0.17.
Current Ratio | 10.26 |
Quick Ratio | 10.18 |
Debt / Equity | 0.17 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -88.44 |
Financial Efficiency
Return on equity (ROE) is -47.52% and return on invested capital (ROIC) is -30.14%.
Return on Equity (ROE) | -47.52% |
Return on Assets (ROA) | -28.15% |
Return on Capital (ROIC) | -30.14% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.28M |
Employee Count | 158 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.34% in the last 52 weeks. The beta is 1.06, so PLRX's price volatility has been similar to the market average.
Beta (5Y) | 1.06 |
52-Week Price Change | -36.34% |
50-Day Moving Average | 13.52 |
200-Day Moving Average | 12.97 |
Relative Strength Index (RSI) | 37.19 |
Average Volume (20 Days) | 577,488 |
Short Selling Information
The latest short interest is 7.17 million, so 11.78% of the outstanding shares have been sold short.
Short Interest | 7.17M |
Short Previous Month | 7.22M |
Short % of Shares Out | 11.78% |
Short % of Float | 15.32% |
Short Ratio (days to cover) | 11.92 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -222.08M |
Pretax Income | -185.41M |
Net Income | -201.68M |
EBITDA | -219.95M |
EBIT | -222.08M |
Earnings Per Share (EPS) | -$3.34 |
Full Income Statement Balance Sheet
The company has $404.51 million in cash and $60.21 million in debt, giving a net cash position of $344.30 million or $5.66 per share.
Cash & Cash Equivalents | 404.51M |
Total Debt | 60.21M |
Net Cash | 344.30M |
Net Cash Per Share | $5.66 |
Equity (Book Value) | 345.82M |
Book Value Per Share | 5.68 |
Working Capital | 370.08M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$132.94 million and capital expenditures -$3.70 million, giving a free cash flow of -$136.64 million.
Operating Cash Flow | -132.94M |
Capital Expenditures | -3.70M |
Free Cash Flow | -136.64M |
FCF Per Share | -$2.25 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
PLRX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -7.77% |
Shareholder Yield | -7.77% |
Earnings Yield | -29.56% |
FCF Yield | -20.03% |
Analyst Forecast
The average price target for PLRX is $40.50, which is 261.29% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $40.50 |
Price Target Difference | 261.29% |
Analyst Consensus | Strong Buy |
Analyst Count | 7 |
Revenue Growth Forecast (5Y) | 156.94% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
PLRX has an Altman Z-Score of 2.43 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.43 |
Piotroski F-Score | 1 |